Status:
COMPLETED
Impact of Microvascular Inflammation on Kidney Allograft Outcome
Lead Sponsor:
Paris Translational Research Center for Organ Transplantation
Conditions:
Transplant;Failure,Kidney
Kidney Transplant Rejection
Eligibility:
All Genders
Brief Summary
Graft microvascular inflammation poses a significant challenge to successful kidney transplantation due to its heterogeneous clinical presentation. There is a critical need to unravel the clinical sig...
Detailed Description
Antibody-mediated rejection is a major cause of graft failure in kidney transplant recipients, with allograft microvascular inflammation serving as the hallmark histological lesion of antibody-mediate...
Eligibility Criteria
Inclusion
- Kidney transplant recipients, with at least one kidney transplant biopsy performed, assessed with the Banff classification.
Exclusion
- Missing data for a rejection-related diagnosis according to the 2019 and 2022 Banff classification.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
6000 Patients enrolled
Trial Details
Trial ID
NCT06496269
Start Date
January 1 2023
End Date
December 31 2023
Last Update
July 11 2024
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric Nephrology, UCLA Mattel Children's Hospital
Los Angeles, California, United States, 90095
2
Division of Pediatric Nephrology, Children's Pediatric Institute
Atlanta, Georgia, United States, 30329
3
Division of Pediatric Nephrology, Children's Mercy Hospital
Kansas City, Missouri, United States, 64108
4
Acute Dialysis Units, Pediatric Kidney Transplant
Charleston, South Carolina, United States, 29425